Abstract
The use of programmed cell death 1 ligand 1 (PD-L1) as a predictive biomarker to select patients to receive programmed cell death 1 (PD-1) or PD-L1 inhibitors in non-small cell lung cancer (NSCLC) is limited by the definitions of positivity, interassay agreement, and intra- and intertumoral heterogeneity of expression. Although PD-L1 expression enriches for responses, the lack of expression does not exclude clinical benefit.
Original language | English (US) |
---|---|
Pages (from-to) | 220-222 |
Number of pages | 3 |
Journal | Clinical pharmacology and therapeutics |
Volume | 100 |
Issue number | 3 |
DOIs | |
State | Published - Sep 2016 |
ASJC Scopus subject areas
- Pharmacology
- Pharmacology (medical)